1048 Randomized controlled trial of the effect of rosiglitazone on carotid atherosclerosis in diabetic patients

There has been much interest in carotid artery wall thickening as a marker of atherosclerosis, both by ultrasound and more recently by magnetic resonance (MR). Ultrasound measurements are limited by the presumption that the vessel is uniform. MR does not have this limitation. Rosiglitazone (RSG) is a nuclear PPAR-gamma agonist and has important effects in diabetes control which has led to its widespread use as a complement to existing diabetes drugs. It is known to lead to minor fluid retention in some patients, and recent reports suggest that it may be associated with an increased risk of ischemic cardiovascular events. However, this effect is controversial and may not be seen with all glitazones.